3 completed, 1 recruiting. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow NLY01: new trials by email Literature Review of NLY01 trials Research Report on NLY01
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis NLY01, Placebo - Multiple Sclerosis | Phase 2 | Recruiting | Johns Hopkins University | 120 | 2026-04-28 | 2026-07-17 |
| A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease NLY01, Vehicle - Parkinson Disease | Phase 2 | Completed | Neuraly, Inc. | 255 | 2020-02-27 | 2024-09-19 |
| A Study With NLY01 in Subjects With Type 2 Diabetes NLY01, Placebo - Type2 Diabetes, Diabetes Mellitus, Type 2 | Phase 2 | Completed | Neuraly, Inc. | 20 | 2019-10-16 | 2021-03-02 |
| A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects NLY01 - Safety and Tolerability in Healthy Volunteers | Phase 1 | Completed | Neuraly, Inc. | 96 | 2018-09-19 | 2019-09-30 |
Diabetes Mellitus, Type 2 (1) · Multiple Sclerosis (1) · Parkinson Disease (1)
Neuraly, Inc. (3) · Johns Hopkins University (1)
United States (3) · Canada (1) · Germany (1)
Dan Lee (2) · Ellen M Mowry, MD, MCR (1) · Emanuel DeNoia, MD (1)